Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 2015-08, Vol.66 (2), p.193-195
1. Verfasser:	Stanton, Robert C., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acidosis, Lactic - chemically induced Diabetes Mellitus, Type 2 - drug therapy Humans Hypoglycemic Agents - adverse effects Metformin - adverse effects Nephrology Renal Insufficiency, Chronic - complications
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	195
container_issue	2
container_start_page	193
container_title	American journal of kidney diseases
container_volume	66
creator	Stanton, Robert C., MD
description
doi_str_mv	10.1053/j.ajkd.2015.04.001
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1699490523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638615006113</els_id><sourcerecordid>1699490523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-50666a591ea813f5f857058e0c65dea25a72dda3b6a4777ed801d6f084f39c573</originalsourceid><addsrcrecordid>eNp9kU-P0zAUxCMEYsvCF-CAfOSS8GzHToIQK9Typ6IrJOiKo-XaL-BsEhfbQSqfnkRdOHDgNJeZ0Xu_ybKnFAoKgr_oCt3d2oIBFQWUBQC9l62oYDyXNa_vZytgFcslr-VF9ijGDgAaLuXD7IKJRgIHusrsNabWh8GN5CYimWV_OiJhZOP0ARNGco1979IUyVeXvpP1x81Lso1km8jeDUiSJzt3wKB79wvJxkc3fiOf0fhhwNHq5PwYrx5nD1rdR3xyp5fZzbu3-_WHfPfp_Xb9ZpebsqYpFyCl1KKhqGvKW9HWogJRIxgpLGomdMWs1fwgdVlVFdoaqJUt1GXLGyMqfpk9P_ceg_8xYUxqcNHM9-sR_RQVlU1TNjATmq3sbDXBxxiwVcfgBh1OioJa6KpOLXTVQldBqWa6c-jZXf90GND-jfzBORtenQ04f_nTYVDROBwNWhfQJGW9-3__63_ipnejM7q_xRPGzk9hnPkpqiJToL4s-y7zUgEgKeX8N0A8nhw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1699490523</pqid></control><display><type>article</type><title>Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Stanton, Robert C., MD</creator><creatorcontrib>Stanton, Robert C., MD</creatorcontrib><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2015.04.001</identifier><identifier>PMID: 25960301</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acidosis, Lactic - chemically induced ; Diabetes Mellitus, Type 2 - drug therapy ; Humans ; Hypoglycemic Agents - adverse effects ; Metformin - adverse effects ; Nephrology ; Renal Insufficiency, Chronic - complications</subject><ispartof>American journal of kidney diseases, 2015-08, Vol.66 (2), p.193-195</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2015 National Kidney Foundation, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-50666a591ea813f5f857058e0c65dea25a72dda3b6a4777ed801d6f084f39c573</citedby><cites>FETCH-LOGICAL-c481t-50666a591ea813f5f857058e0c65dea25a72dda3b6a4777ed801d6f084f39c573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2015.04.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25960301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stanton, Robert C., MD</creatorcontrib><title>Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><subject>Acidosis, Lactic - chemically induced</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Metformin - adverse effects</subject><subject>Nephrology</subject><subject>Renal Insufficiency, Chronic - complications</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-P0zAUxCMEYsvCF-CAfOSS8GzHToIQK9Typ6IrJOiKo-XaL-BsEhfbQSqfnkRdOHDgNJeZ0Xu_ybKnFAoKgr_oCt3d2oIBFQWUBQC9l62oYDyXNa_vZytgFcslr-VF9ijGDgAaLuXD7IKJRgIHusrsNabWh8GN5CYimWV_OiJhZOP0ARNGco1979IUyVeXvpP1x81Lso1km8jeDUiSJzt3wKB79wvJxkc3fiOf0fhhwNHq5PwYrx5nD1rdR3xyp5fZzbu3-_WHfPfp_Xb9ZpebsqYpFyCl1KKhqGvKW9HWogJRIxgpLGomdMWs1fwgdVlVFdoaqJUt1GXLGyMqfpk9P_ceg_8xYUxqcNHM9-sR_RQVlU1TNjATmq3sbDXBxxiwVcfgBh1OioJa6KpOLXTVQldBqWa6c-jZXf90GND-jfzBORtenQ04f_nTYVDROBwNWhfQJGW9-3__63_ipnejM7q_xRPGzk9hnPkpqiJToL4s-y7zUgEgKeX8N0A8nhw</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Stanton, Robert C., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150801</creationdate><title>Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?</title><author>Stanton, Robert C., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-50666a591ea813f5f857058e0c65dea25a72dda3b6a4777ed801d6f084f39c573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acidosis, Lactic - chemically induced</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Metformin - adverse effects</topic><topic>Nephrology</topic><topic>Renal Insufficiency, Chronic - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stanton, Robert C., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stanton, Robert C., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>66</volume><issue>2</issue><spage>193</spage><epage>195</epage><pages>193-195</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25960301</pmid><doi>10.1053/j.ajkd.2015.04.001</doi><tpages>3</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0272-6386
ispartof	American journal of kidney diseases, 2015-08, Vol.66 (2), p.193-195
issn	0272-6386 1523-6838
language	eng
recordid	cdi_proquest_miscellaneous_1699490523
source	MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects	Acidosis, Lactic - chemically induced Diabetes Mellitus, Type 2 - drug therapy Humans Hypoglycemic Agents - adverse effects Metformin - adverse effects Nephrology Renal Insufficiency, Chronic - complications
title	Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T06%3A10%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metformin%20Use%20in%20Type%202%20Diabetes%20Mellitus%20With%20CKD:%20Is%20It%20Time%20to%20Liberalize%20Dosing%20Recommendations?&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Stanton,%20Robert%20C.,%20MD&rft.date=2015-08-01&rft.volume=66&rft.issue=2&rft.spage=193&rft.epage=195&rft.pages=193-195&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2015.04.001&rft_dat=%3Cproquest_cross%3E1699490523%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1699490523&rft_id=info:pmid/25960301&rft_els_id=S0272638615006113&rfr_iscdi=true